Evidence map›Paper›PMID 32564243›Full record

ArticleInternational journal of hematology2020

A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Keizo Horibe, Joan D Morris, Catherine A Tuglus, Cedric Dos Santos, James Kalabus, Abraham Anderson, Hiroaki Goto, Chitose Ogawa

2 registry-linked trialsAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02412306 phase1 / phase2completednot on this map

A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)

TypeinterventionalSponsorAmgenRan2015 to 2019Enrolled66ConditionsRelapsed Refractory B Precursor Acute Lymphoblastic LeukemiaArmsBlinatumomab
NCT06607419 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

TypeinterventionalSponsorShanghai Jiao Tong University School of MedicineRan2024 to 2030Enrolled90ConditionsB-Cell Lymphoblastic LeukemiaArmsBlinatumomab
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Keizo HoribeDepartment of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan. keizo.horibe@nnh.go.jp.ORCID http://orcid.org/0000-0002-6251-6059
Joan D MorrisClinical Development, Amgen Inc., Thousand Oaks, CA, USA.
Catherine A TuglusGlobal Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
Cedric Dos SantosClinical Biomarkers, Amgen Inc., South San Francisco, CA, USA.
James KalabusClinical Pharmacology, Amgen Inc., South San Francisco, CA, USA.
Abraham AndersonClinical Biomarkers, Amgen Inc., Thousand Oaks, CA, USA.
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center Hospital, Chūō, Tokyo, Japan.
Amgen (United States) · USKanagawa Children's Medical Center · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapies are needed for children with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific T-cell engager immunotherapy that simultaneously binds to CD3-positive cytotoxic T cells and CD19-positive B cells and redirects the patient's T cells to lyse malignant and normal B cells. We conducted an open-label phase 1b study to determine the safety, pharmacokinetics, efficacy, and recommended dose of blinatumomab in Japanese children with R/R B-cell precursor ALL. Patients received induction blinatumomab for 4 weeks (5 μg/m

Indexed as

B-LymphocytesImmunotherapyT-LymphocytesAdolescentAntibodies, BispecificAntineoplastic AgentsAsian PeopleChildDrug Administration ScheduleFemaleHumansMaleMaximum Tolerated DosePrecursor B-Cell Lymphoblastic Leukemia-LymphomaRemission InductionSafetyAntibodies, BispecificAntineoplastic AgentsblinatumomabAcute lymphoblastic leukemiaBlinatumomabJapanPediatricPhase 1b clinical trial

Identifiers

PMID32564243
OpenAlexW3036414958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.